Varlilumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Varlilumab
Accession Number
DB11930
Description

Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
  • CDX-1127

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Varlilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Varlilumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Varlilumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Varlilumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Varlilumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Varlilumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Varlilumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Varlilumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Varlilumab.
AvelumabThe risk or severity of adverse effects can be increased when Varlilumab is combined with Avelumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
0125DUV5XC
CAS number
1393344-72-3

References

General References
Not Available
PubChem Substance
347911259
Wikipedia
Varlilumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentALK-Positive Large B-Cell Lymphoma / Atypical Burkitt/Burkitt-Like Lymphoma / Burkitt-Like Lymphoma With 11q Aberration / Diffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation / Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / EBV-Positive Mucocutaneous Ulcer / High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Human Herpesvirus 8-Positive Neoplastic Cells Present / Intravascular Large B-Cell Lymphoma / Large B-Cell Lymphoma With IRF4 Rearrangement / Plasmablastic Lymphoma / Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Primary Effusion Lymphomas / Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Lymphomatoid Granulomatosis / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
2RecruitingTreatmentGlioblastomas1
2TerminatedTreatmentMelanoma1
1CompletedTreatmentAdvanced Breast Carcinoma / Advanced Ovarian Carcinoma1
1CompletedTreatmentAny T-cell Malignancy / Burkett's Lymphoma / CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma / CD27 Expressing B-cell Malignancies, (for Example: Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia, Burkett's Lymphoma / Colorectal Adenocarcinoma, Non-small Cell Lung Cancer) / Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer / Mantle Cell Lymphoma (MCL) / Mantle Cell Lymphoma, Primary Lymphoma of the Central Nervous System / Marginal Zone B Cell Lymphoma) / Primary Lymphoma of the Central Nervous System / Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma1
1RecruitingTreatmentAstrocytoma, Grade II / Glioma, Astrocytic / Gliomas / Gliomas, Malignant / Oligoastrocytoma, Mixed / Oligodendrogliomas1
1RecruitingTreatmentMetastatic Lung Non-Small Cell Carcinoma / Refractory Lung Non-Small Cell Carcinoma / Stage III Lung Cancer AJCC v8 / Stage IIIA Lung Cancer AJCC v8 / Stage IIIB Lung Cancer AJCC v8 / Stage IIIC Lung Cancer AJCC v8 / Stage IV Lung Cancer AJCC v8 / Unresectable Lung Non-Small Cell Carcinoma1
1TerminatedTreatmentCancer, Bladder / Clear-cell Metastatic Renal Cell Carcinoma / Genitourinary tract neoplasm / Head and Neck Carcinoma / Kidney Diseases / Melanoma / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Kidney / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Triple Negative Breast Cancer (TNBC) / Urologic Diseases / Urologic Neoplasms1
1TerminatedTreatmentClear-cell Metastatic Renal Cell Carcinoma / Genitourinary tract neoplasm / Kidney Diseases / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Kidney / Renal Cell Adenocarcinoma / Urologic Diseases / Urologic Neoplasms1
1TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 15:01 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates